Nomination Committee for Orexo´s Annual General Meeting 2007

At Orexo AB;s Annual General Meeting on 27 April 2006, it was resolved that the Chairman of the Board of Directors shall, not later than six months before the Annual General Meeting, announce a Nomination Committee comprising one representative for each of the three largest shareholders in terms of the number of votes.

Following a contact with the company's three largest shareholders, the following members have been nominated:

-Per Samuelsson, HealthCap AB, (37.27 percent of capital and votes);
-Thomas Halvorsen, Fjärde AP-fonden, (8.97 percent of capital and votes); and
-Thomas Ehlin, Nordea Fonder (4.99 percent of capital and votes).

The Nomination Committee represents in total approximately 51.23 per cent of the capital and votes in the company as of October 31, 2006.

The Nomination Committee's proposal for Board of Directors will be announced in the notice for the Annual General Meeting 2007 and on the corporate web site, www.orexo.com.

The Annual General Meeting in Orexo AB will be held on Monday 23 April 2007, at 5 p.m. CET. in Stockholm, Sweden.


For further information, please contact:
Zsolt Lavotha, President and CEO, Orexo AB
+46 (0)18 780 88 12, e-mail: zsolt.lavotha@orexo.se

Claes Wenthzel, Executive Vice President and CFO, Orexo AB
+46 (0)18 780 88 44, +46 (0)708-62 01 22 , e-mail: claes.wenthzel@orexo.se

About Us

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies.The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.

Subscribe

Documents & Links